IRWD
NASDAQIronwood Pharmaceuticals Inc.
News · 26 weeks43-20%
2026-03-012026-08-23
Mix2090d
- Insider10(50%)
- SEC Filings4(20%)
- Other3(15%)
- Earnings2(10%)
- Leadership1(5%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Ironwood Pharmaceuticals Inc.SCHEDULE 13G - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
- SECSEC Form 10-Q filed by Ironwood Pharmaceuticals Inc.10-Q - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
- SECIronwood Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
- PRIronwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results– Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than 30% increase year-over-year; Raises total revenue guidance to $460 - $485 million and adjusted EBITDA guidance to greater than $310 million – – Q2 2026 LINZESS U.S. net sales of $282 million; $555 million year-to-date representing 44% year-over-year growth – – Total revenue of $113 million, GAAP net income of $51 million and adjusted EBITDA of $83 million in Q2 2026; repaid $200 million convertible notes with cash on hand – – Confirmatory Phase 3 STARS-2 trial of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) now actively recruiting patients
- PRIronwood Pharmaceuticals to Host Second Quarter 2026 Investor Update CallIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD), today announced it will host its second quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 6, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) using conference ID number and event passcode 3647053. To access the webcast, please visit the Investors & Media section of Ironwood’s website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, August 6, 2026, at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, August 20, 2026. To listen
- INSIDERSVP, CMO, Head-Res&Drug Silber Jeffrey was granted 137,036 shares (SEC Form 4)4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
- INSIDERSEC Form 3 filed by new insider Silber Jeffrey3 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
- PRIronwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients– Ironwood Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline to Retire After 30-Year Career Advancing GI Science and Patient Care – – Dr. Silber, a Drug Development Veteran, Will Lead Ironwood’s Next Phase of R&D Strategy and Execution – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey Silber as his successor. Dr. Silber will oversee Research and Drug Developmen
- INSIDERPFO & PAO Silver Ronald sold $578,063 worth of shares (127,890 units at $4.52) as part of a pre-agreed trading plan, decreasing direct ownership by 29% to 313,680 units (SEC Form 4)4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
- SECIronwood Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
- INSIDERDirector Shepard Jay was granted 63,481 shares, increasing direct ownership by 37% to 235,036 units (SEC Form 4)4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
- INSIDERDirector Kessler Marla L was granted 63,481 shares, increasing direct ownership by 38% to 229,364 units (SEC Form 4)4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
- INSIDERDirector Currie Mark G was granted 63,481 shares, increasing direct ownership by 10% to 676,900 units (SEC Form 4)4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
- INSIDERDirector Duane Jon R was granted 63,481 shares, increasing direct ownership by 33% to 253,820 units (SEC Form 4)4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
- INSIDERDirector Denner Alexander J was granted 67,546 shares, increasing direct ownership by 26% to 323,855 units (SEC Form 4)4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
- INSIDERDirector Mchugh Julie sold $80,460 worth of shares (21,571 units at $3.73) as part of a pre-agreed trading plan and was granted 63,481 shares, increasing direct ownership by 20% to 250,749 units (SEC Form 4)4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
- INSIDERDirector Moukheibir Catherine was granted 63,481 shares, increasing direct ownership by 54% to 181,425 units (SEC Form 4)4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
- SECIronwood Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
- PRIronwood Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD), today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4th at 11:05 a.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide,
- PRFDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)– Expanded indication extends availability to children ages 2-5 with FC; previously approved in pediatric patients 6 years of age and older – – LINZESS remains the first-and-only FDA-approved prescription therapy for pediatric FC – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of LINZESS® (linaclotide) in pediatric patients 2 years of age and older with functional constipation (FC). LINZESS was previously approved for pediatric patients 6 years and older with FC.
- SECAmendment: Ironwood Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
- INSIDERPFO & PAO Silver Ronald was granted 25,000 shares, increasing direct ownership by 6% to 441,570 units (SEC Form 4)4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ironwood Pharmaceuticals Inc.SCHEDULE 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)
- SECIronwood Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
- SECSEC Form 10-Q filed by Ironwood Pharmaceuticals Inc.10-Q - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)
IRWD FAQ
7 questionsWhat does Ironwood Pharmaceuticals Inc. do?
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions...Where does IRWD stock trade?
Ironwood Pharmaceuticals Inc. (IRWD) is listed on NASDAQ.What sector and industry is IRWD in?
Ironwood Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Ironwood Pharmaceuticals Inc. go public?
Ironwood Pharmaceuticals Inc. (IRWD) completed its IPO in 2010.What are analysts saying about IRWD?
Ironwood Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Citizens JMP: Mkt Outperform with a $800.00 price target on 2026-01-05.What companies are similar to IRWD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IRWD side-by-side with any of them on Quantisnow.How can I track IRWD on Quantisnow?
Quantisnow aggregates Ironwood Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IRWD to receive live email and push alerts on every new disclosure.